Lv1
30 积分 2025-05-29 加入
POS1160 A PHASE IB, MULTICENTRE, OPEN-LABEL, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SUBCUTANEOUSLY ADMINISTERED MOSUNETUZUMAB IN PARTICIPANTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
1个月前
已关闭
POS1113 TREATMENT OF SEVERE SYSTEMIC SCLEROSIS WITH BLINATUMOMAB, A BISPECIFIC ANTI-CD3/CD19 T CELL ENGAGER
1个月前
已完结
Teclistamab in relapsed systemic sclerosis after autologous haematopoietic stem cell transplantation
1个月前
已完结
Establishment of Membrane-Bound IgA1-Specific Antibody Possessing Antibody-Dependent Cellular Cytotoxicity Activity
3个月前
已完结
Complement inhibitors and B-cell modifying agents for IgA nephropathy- a KDIGO commentary
5个月前
已关闭
Single-Cell Transcriptomic Analysis of Terminal Ileum and Peripheral Blood Identifies B Cell Maturation Antigen (BCMA) as a Therapeutic Target in IgAN
6个月前
已关闭
Mucosal vaccination in mice provides protection from diverse respiratory threats
6个月前
已完结
Optimizing CAART for evolving antibody landscapes
6个月前
已关闭
Recent discoveries on the acquisition of the highest levels of human performance
7个月前
已完结
皖公网安备34019202002308
